Journal Pre-proof

Increasing incidence of microscopic colitis in a population-based cohort study in Switzerland

Hugo Maye, Ekaterina Safroneeva, Sébastien Godat, Christine Sempoux, Pu Yan, Hanifa Bouzourène, Walter Seelentag, Edouard Stauffer, Lorenzo Taminelli, Frank Seibold, Alain M. Schoepfer, MD

PII: S1542-3565(20)31427-0
DOI: <https://doi.org/10.1016/j.cgh.2020.10.015>
Reference: YJCGH 57553

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 9 October 2020

Please cite this article as: Maye H, Safroneeva E, Godat S, Sempoux C, Yan P, Bouzourène H, Seelentag W, Stauffer E, Taminelli L, Seibold F, Schoepfer AM, Increasing incidence of microscopic colitis in a population-based cohort study in Switzerland, *Clinical Gastroenterology and Hepatology* (2020), doi: <https://doi.org/10.1016/j.cgh.2020.10.015>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 by the AGA Institute

Submission to CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Increasing incidence of microscopic colitis in a population-based cohort study in Switzerland

Hugo Maye¹, Ekaterina Safroneeva², Sébastien Godat¹, Christine Sempoux³, Pu Yan⁴, Hanifa Bouzourène⁵, Walter Seelentag⁶, Edouard Stauffer⁷, Lorenzo Taminelli⁸, Frank Seibold⁹, Alain M. Schoepfer, MD¹

1 Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

2 Institute of Social and Preventive Medicine, University of Bern, Switzerland

3 Institute of Pathology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

4 Argot Laboratoire SA, Rue due Liseron 5, 1006 Lausanne, Switzerland

5 Unilabs Laboratoire SA, Rue de la Vigie 5, 1003 Lausanne, Switzerland

6 Institut de Pathologie Romand, Route de Denges 2, 1027 Lonay, Switzerland

7 Promed Laboratoire SA, Route de l'Ancienne Papeterie 131, 1723 Marly, Switzerland

8 Aurigen Laboratoire SA, Avenue de Sévelin 18, 1004 Lausanne, Switzerland

9 Cabinet de gastroentérologie Balsiger, Seibold & partenaires, Chemin des Pensionnats 1, 1752 Villars-sur-Glâne

25

26

27 Correspondence address:

28 Professor Alain Schoepfer, MD

29 Division of Gastroenterology and Hepatology

30 Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne

31 Rue de Bugnon 44, 07/2425

32 1011 Lausanne, Switzerland

33 Telephone number: +21 314 71 58

34 e-mail: alain.schoepfer@chuv.ch

35

36 **Conflict of interest:** none for all authors37 **Funding:** none

38

39 **Word count:** 740 words (without table and references)

40

41

42

43

INTRODUCTION

Microscopic colitis (MC) is a chronic inflammatory disease of the colon that presents with chronic, non-bloody watery diarrhea and only few or no endoscopic abnormalities. Histologic examination discriminates lymphocytic colitis (LyC; presence of ≥ 20 intraepithelial lymphocytes per 100 surface epithelial cells) and collagenous colitis (CC; colonic subepithelial collagen band >10 micrometers in diameter).[1,2] MC not otherwise specified (NOS) describes a subgroup of patients who do not fulfill the diagnostic criteria for either CC or LyC.[1,2] Population-based epidemiologic data regarding MC are scarce. We aimed to evaluate the clinical presentation at diagnosis, incidence and prevalence of MC in Cantons of Vaud and Fribourg, Switzerland.

METHODS

Cantons of Vaud and Fribourg lie in the French speaking, Western part of Switzerland. As of 12/2017, both cantons together had a population of 1,109,230 inhabitants. After having identified MC patients through databases of all Pathology institutes (n=6) serving both cantons and a histology slide review to assure correctness of diagnosis, we performed a chart review in practices of all gastroenterologists covering both cantons (n=42). The study was approved by the ethics committee of Cantons of Vaud and Fribourg (CER-VD 306/15). Two hundred and fifty-two patients with MC, diagnosed between January 1994 and December 2017, were identified. Of these, 34 were excluded for having NOS. We

calculated incidence rates using data provided by the Institutes of population statistics of Canton of Vaud and Fribourg.

RESULTS

Of the 218 patients with MC, 123 (56.4%) had LyC and 95 (43.6%) had CC. Seventy-four percent (162/218) of MC patients were female, mean age at first symptoms was 62 ± 15.4 years (range 24-89), mean age at MC diagnosis was 63.2 ± 14.3 years (range 29-89). All MC patients suffered from diarrhea, followed by abdominal pain (31.7%), weight loss (31.2%), bloating (20.6%), fatigue (9.6%), nausea / vomiting (3.2%). Exposure to risk factors for MC were frequently found and included HMG-CoA reductase inhibitors (27.1%), non-steroidal anti-inflammatory drugs (14.2%), proton-pump inhibitors (22.5%), serotonin reuptake inhibitors (22.5%), and smoking (20.2%). Infectious agents were searched and excluded as cause of chronic diarrhea in all included patients.

A colonoscopy was performed as diagnostic tool in all of the 218 patients. In 74.3% of patients the colonoscopy was normal. Polyps were found in 16.5% of MC patients, followed by edema (9.2%), erythema (4.6%), and an erosion (0.5%). Median thickness of the subepithelial collagen band in patients with CC was $25 \mu\text{m}$, whereas patients with LyC had a median of 35 intra-epithelial lymphocytes per 100 epithelial cells.

Oral budesonide was most frequently used as first therapy (72.9%), followed by loperamide (66.1%), aminosalicylates (16.1%), and cholestyramine (12.8%).

Incidence rates were calculated and are shown together with the cumulative prevalence in **Table 1**. No patient was diagnosed with MC prior to 1994. Incidence of MC significantly increased from 0.36/100,000 person-years in 1994-1997 to 6.85/100,000 person-years in 2017 ($p=0.025$, trend test). The cumulative prevalence of MC, LyC, and CC in 2017 was 19.65/100,000, 11.09/100,000, and 8.56/100,000, respectively. As such, the current prevalences for MC, LyC, and CC are 1/5,088 persons, 1/9018 persons, and 1/11,676 persons, respectively.

DISCUSSION

Our population-based study from Western Switzerland found a steady increase in incidence of MC during the last two decades. Findings of our study are in accordance with the results of a systematic review and meta-analysis that reported pooled incidence rates for CC of 4.14 (95% CI 2.89-5.40) per 100,000 person-years and 4.85 (95% CI 3.45-6.25) for LyC. Bergman et al. assessed the incidence of MC in Sweden from 1995-2015 in a nationwide cohort. Among 13,844 patients, incidence of MC was 10.5/100,000 as from 2006 which is roughly 6 times higher when compared to our findings.[4] Our data are comparable with the results of Fernandez-Banares et al. who found lower incidences (2.2/100,000 for LyC and 2.6/100,000 for CC) among 290,000 inhabitants in Spain.[5] These results reinforce the existence of a north-south gradient of MC which has been described by several groups.[3]

Strengths of our study are that all gastroenterologists and pathologists working in Cantons of Vaud and Fribourg collaborated in this project which is

crucial for the generation of population-based data. Limitations of our study are related to its retrospective design that impairs the generation of high-quality data to evaluate questions regarding the natural history of MC such as therapeutic response to different drugs.

In conclusion, in the first Swiss population-based study we found that MC incidence was steadily increasing over the last two decades. Compared to other countries, MC incidences are low in the population we studied.

Funding sources: none

Medical writing: none

Conflict of interest relevant to this study: none for all authors

REFERENCES

- 1 Münch A, Dust A, Bohr J, Bonderup O, Fernandez-Banares F, Hjortswang H, et al. Microscopic colitis : current status, present and future challenges. *J Crohns Colitis* 2012;6:932-45.
- 2 Nguyen GC, Smalley WE, Vege SS, Carrasco-Labra A, and the Clinical Guidelines Committee: American gastroenterological association institute guideline on the medical treatment of microscopic colitis. *Gastroenterology* 2016;150:242-6.
- 3 Tong J, Zheng Q, Zhang C, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. *Am J Gastroenterol* 2015;110:265-76.
- 4 Bergman D, Clements MS, Khalili H, Agréus L, Hultcrantz R, Ludvigsson JF. A nationwide cohort study of the incidence of microscopic colitis in Sweden. *Aliment Pharmacol Ther* 2019;49:1395-1400.
- 5 Fernandez-Banares F, Salas A, Esteve M, Pardo L, Casalots J, Forne M, et al. Evolution of the incidence of collagenous colitis and lymphocytic colitis in Terrassa, Spain: a population-based study. *Inflamm Bowel Dis* 2011;17:1015–20.

TABLES

Table 1: Incidence (plus 95% confidence intervals) and prevalence of MC, LyC, and CC from 1994 to 2017. The incidence is shown per 100,000 inhabitants, stratified according to 4 year intervals and per year. The prevalence was calculated per 100,000 inhabitants at the end of the respective 4 year interval.

Interval	1994-1997	1998-2001	2002-2005	2006-2009	2010-2013	2014-2017
Population Vaud + Fribourg	839,965	856,091	901,168	967,802	1,027,985	1,109,230
MC new cases	3	8	22	45	64	76
MC incidence per 4 year interval	0.36, 0-0.48	0.93, 0.48-1.4	2.44, 2.2-2.68	4.7, 3.32-5.8	6.23, 5.44-7	6.85, 6.12-7.56
MC incidence per year	0.09	0.23	0.61	1.18	1.56	1.71
MC prevalence	0.36	1.29	3.66	8.06	13.81	19.65
LyC new cases	1	5	16	27	35	39
LyC incidence per 4 year interval	0.12, 0-0.48	0.58, 0.48-0.92	1.78, 1.32-2.2	2.79, 2.48-3.32	3.41, 2.72-3.88	3.52, 2.88-3.96
LyC incidence per year	0.03	1.5	0.45	0.7	0.85	0.88
LyC prevalence	0.12	0.7	2.44	5.06	8.17	11.09
CC new cases	2	3	6	18	29	37
CC incidence per 4 year interval	0.24, 0-0.48	0.35, 0-0.48	0.67, 0.48-0.89	1.86, 1.24-2.48	2.92, 2.72-3.12	3.34, 2.88-3.6
CC incidence per year	0.06	0.09	0.17	0.47	0.73	0.84
CC prevalence	0.24	0.58	1.22	2.99	5.64	8.56

TABLES

Table 1: Incidence (plus 95% confidence intervals) and prevalence of MC, , LyC and CC from 1994 to 2017. The incidence is shown per 100,000 inhabitants, stratified according to 4 year intervals and per year. The prevalence was calculated per 100,000 inhabitants at the end of the respective 4 year interval.

Interval	1994-1997	1998-2001	2002-2005	2006-2009	2010-2013	2014-2017
Population Vaud + Fribourg	839,965	856,091	901,168	967,802	1,027,985	1,109,230
MC new cases	3	8	22	45	64	76
MC incidence per 4 year interval	0.36, 0-0.48	0.93, 0.48-1.4	2.44, 2.2-2.68	4.7, 3.32-5.8	6.23, 5.44-7	6.85, 6.12-7.56
MC incidence per year	0.09	0.23	0.61	1.18	1.56	1.71
MC prevalence	0.36	1.29	3.66	8.06	13.81	19.65
LyC new cases	1	5	16	27	35	39
LyC incidence per 4 year interval	0.12, 0-0.48	0.58, 0.48-0.92	1.78, 1.32-2.2	2.79, 2.48-3.32	3.41, 2.72-3.88	3.52, 2.88-3.96
LyC incidence per year	0.03	1.5	0.45	0.7	0.85	0.88
LyC prevalence	0.12	0.7	2.44	5.06	8.17	11.09
CC new cases	2	3	6	18	29	37
CC incidence per 4 year interval	0.24, 0-0.48	0.35, 0-0.48	0.67, 0.48-0.89	1.86, 1.24-2.48	2.92, 2.72-3.12	3.34, 2.88-3.6
CC incidence per year	0.06	0.09	0.17	0.47	0.73	0.84
CC prevalence	0.24	0.58	1.22	2.99	5.64	8.56

Journal Pre-proof